# 119-s-483: Responsibility in Drug Advertising Act of 2025

119-s-483, Responsibility in Drug Advertising Act of 2025, is a 119th Congress bill sponsored by Sen. King, Angus S., Jr. [I-ME] (I-ME); status introduced; PRIA reads it as touching household money (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-s-483
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-483
- Congress: 119
- Title: Responsibility in Drug Advertising Act of 2025
- Status: introduced
- Introduced: 2025-02-06
- Sponsor: Sen. King, Angus S., Jr. [I-ME] (I-ME)
- Cosponsors: 2
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-04-21

## Summary

**A three-year ban on direct-to-consumer advertising for newly approved prescription drugs** would stop companies from promoting new medicines directly to the public while regulators gather more safety and value evidence. The ban covers social media, allows the Food and Drug Administration to grant a waiver in the third year if advertising shows affirmative public health value, and lets the agency extend the ban later if post-approval studies or reports identify significant safety problems. - Families and patients: Exposure to promotional ads for new drugs would be limited for the first three years, so early information about new treatments is more likely to come from clinicians and regulators than from adverts. - Drug sponsors: Companies could not run direct-to-consumer campaigns, including on social media, during that initial period unless they win a third-year waiver that demonstrates public health benefit. They also face possible renewed advertising bans if safety signals appear after approval. - Food and Drug Administration and enforcement: The bill would require the FDA to revise advertising rules within one year and creates a specific statutory violation to help enforce the advertising restrictions under existing authorities.

## Cosponsors (2)

- Sen. Kaine, Tim [D-VA] (D-VA), 2025-02-06T00:00:00.000Z
- Sen. Welch, Peter [D-VT] (D-VT), 2025-02-06T00:00:00.000Z

## Provisions PRIA read

- Limits drug ads for newly approved drugs: benefit, medium. If enacted, the bill would ban direct-to-consumer ads for prescription drugs for three years after FDA approval. The ban would include ads on social media. It would apply only to drugs approved on or after one year before enactment. In the third year, a drug sponsor could apply for a waiver. The Se…

## Related bills

- 119-s-2763: Keep Billionaires Out of Social Security Act
- 119-s-3869: Healthy Families Act
- 119-s-5108: Right to IVF Act of 2026
- 119-s-1503: Equality Act
- 119-s-2295: Child Care for Working Families Act
- 119-s-1748: Kids Online Safety Act

## Sources
- [119-s-483 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/483)

## Related
- [119-s-2763: Keep Billionaires Out of Social Security Act](https://policyrisk.com/legislation/119-s-2763)
- [119-s-3869: Healthy Families Act](https://policyrisk.com/legislation/119-s-3869)
- [119-s-5108: Right to IVF Act of 2026](https://policyrisk.com/legislation/119-s-5108)
- [119-s-1503: Equality Act](https://policyrisk.com/legislation/119-s-1503)
- [119-s-2295: Child Care for Working Families Act](https://policyrisk.com/legislation/119-s-2295)
- [119-s-1748: Kids Online Safety Act](https://policyrisk.com/legislation/119-s-1748)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-483 (as of 2026-04-21).